Related Experiment Video
Updated: Jan 11, 2026
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Clinical Outcomes in Patients With COPD With Disease Stability: Data from the Korea COPD Subgroup Study Cohort
Eunjeong Son1, Hyewon Seo2, Seung Won Ra3
1Division of Respiratory and Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
Background:
COPD is a heterogeneous disease with progressive airflow limitation. Despite therapeutic advances, current treatments poorly halt COPD progression. Disease stability (DS) is a proposed treatment goal, but its clinical significance remains uncertain.
Research Question:
What are the differences in lung function decline, exacerbation risk, and mortality between patients with COPD with and without DS?
Study Design And Methods:
This study analyzed data from the Korean COPD Subgroup Study, a nationwide prospective cohort of patients with COPD in South Korea. Participants were ≥ 40 years of age and had a postbronchodilator FEV1/FVC ratio < 0.70. Ten-year all-cause mortality data were obtained from national death records and merged with cohort data. DS (+) was defined as the absence of moderate-to-severe exacerbations, no decline in FEV1, and no worsening of the St. George's Respiratory questionnaire score during the first year. Clinical outcomes were compared between patients with DS (+) and patients without DS (+), who were classified as DS (-).
Results:
Among 1,639 patients analyzed, 147 (9.0%) achieved DS (+), whereas 1,492 (91.0%) were classified as DS (-). Baseline characteristics were similar between groups. Compared with the DS (-) group, the DS (+) group exhibited significantly lower rates of moderate-to-severe exacerbations (incidence rate ratio, 0.30; P = .033) and severe exacerbations (incidence rate ratio, 0.26; P = .002). Paradoxically, the annual decline in FEV1 was greater in the DS (+) group (-45.8 vs -10.3 mL/y; P < .001). Multivariable Cox regression analysis demonstrated that DS (+) status was independently associated with a significantly reduced risk of all-cause mortality (adjusted hazard ratio, 0.56; P = .036).
Interpretation:
Patients with COPD with DS (+) showed reduced exacerbations and mortality. These findings support DS as a clinically meaningful and achievable treatment target in COPD, with potential utility in guiding personalized disease management.
More Related Videos
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation